The Vectura board has recommended PMI's 165 pence-per-share offer to shareholdersRead More
Tags :Vectura
The inhaled drug manufacturer’s directors describe the bid as “fair and reasonable.”Read More
The private equity firm’s bid for Vectura remains lower than that made by PMI. Read More
The move comes after a counteroffer from Carlyle for the drug delivery solutions provider. Read More
Government is uncomfortable with a tobacco firm 'profiting from respiratory ailments.' Read More
The Vectura board reportedly recommended the offer based purely on its value.Read More
